Skip to main content
. Author manuscript; available in PMC: 2020 Feb 4.
Published in final edited form as: Sci Transl Med. 2019 May 29;11(494):eaau9087. doi: 10.1126/scitranslmed.aau9087

Fig. 6. Myeloma cell α6 enhances PRC2 expression through the ERK1/2 and NF-κB signaling pathways in adipocytes.

Fig. 6.

(A) Schematic of coculture systems. (B) Western blots showing the expression of EZH2 and SUZ12 in normal adipocytes or adipocytes exposed to myeloma cells through direct or nondirect contact manner. (C) Expression of EZH2 mRNAs in the adipocytes directly contacted with myeloma cells in the presence of blocking antibodies against integrins. (D) Western blots showing the expression of integrin α6 (ITGA6) in normal plasma cells isolated from normal BM (n = 3), primary myeloma cells isolated from patients (n = 4), and myeloma cell lines (n = 6). (E) Expression of ITGA6 in nonspecific or α 6 shRNA–expressing myeloma cells. (F and G) Western blots showing the expression of EZH2, SUZ12, and PPARγ (F) and the expression of nonphosphorylated or phosphorylated (p) kinases in the adipocytes cocultured with nonspecific or α6 shRNA–expressing myeloma cells for 24 hours (G). (H and I) Expression of pERK1/2, pIκBα, EZH2, and SUZ12 in the adipocytes treated without or with U0126 (H) or BAY11–7085 (I). The expression of β-actin served as loading controls. Data are averages ± SD. Each experiment was repeated three times. **P < 0.01. All P values were determined using one-way ANOVA.